SCHEMBL249237

SCHEMBL249237

C=CCN(CC=C)c1ccc2cccc(O)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTDSP1 Q9GZU7 1/20 0.45
▸ CYP1A2 P05177 1/20 0.40
▸ DHFR P00374 2/20 0.38
▸ INSR P06213 1/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ PTPN1 P18031 3/20 0.36
▸ GRIN2D O15399 2/20 0.35
▸ GRIN2A Q12879 2/20 0.35
▸ GRIN2B Q13224 2/20 0.35
▸ GRIN2C Q14957 2/20 0.35
▸ MCL1 Q07820 1/20 0.35
▸ OPRM1 P35372 2/20 0.35
▸ OPRD1 P41143 2/20 0.35
▸ OPRK1 P41145 2/20 0.35
▸ PLAU P00749 1/20 0.34
▸ GRIN3B O60391 1/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN3A Q8TCU5 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8057151 0.76 PLAU (0.41) DHFRPLAUKDM4EALDH1A1HPGD
SCHEMBL10935728 0.76 INSR (0.46) CYP1A2DHFRINSRIGF1RKDM4E
SCHEMBL5697319 0.76 CTDSP1 (0.53) CTDSP1CYP1A2GRIN2DGRIN2AGRIN2B
SCHEMBL10694157 0.73 CHKA (0.41) DHFRPTPN1GRIN2DGRIN2AGRIN2B
SCHEMBL10769370 0.73 CYP1A2 (0.39) CYP1A2DHFRKDM4E
SCHEMBL5306209 0.73 ALDH1A1 (0.58) PTPN1GRIN2DGRIN2AGRIN2BGRIN2C
SCHEMBL249054 0.72 HTR1B (0.45) KDM4EALDH1A1HPGDATM
SCHEMBL9278793 0.71 PTPN1 (0.36) DHFRINSRIGF1RPTPN1OPRM1
SCHEMBL5386689 0.69 TERT (0.58) DHFROPRM1ALDH1A1HPGD
SCHEMBL11963906 0.69 CTDSP1 (0.53) CTDSP1CYP1A2GRIN2DGRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1339663-B1 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2012-01-04 — — EP disclosed
EP-2338886-A2 Naphthalene derivatives Novartis AG (CH) 2011-06-29 — — EP disclosed
US-7045533-B2 Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout NOVARTIS AG (CH) 2006-05-16 — — US disclosed
US-20040053890-A1 Naphthalene derivatives NOVARTIS AG (CH) 2004-03-18 — — US disclosed
EP-1339663-A2 NAPHTHALENE DERIVATIVES Novartis AG (CH) 2003-09-03 — — EP disclosed
WO-2002042248-A2 NAPHTHALENE DERIVATIVES NOVARTIS AG (CH) 2002-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053890-A1 Naphthalene derivatives CYP1A1, SULT1E1, CYP2F1 CTDSP1 3630/4885CYP1A2 11/4885DHFR 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback